Can an arthritis drug tame brain inflammation in Alzheimer's and ALS?
NCT ID NCT05189106
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-phase study tested the drug baricitinib in 17 people with Alzheimer's disease, ALS, or mild cognitive problems. The goal was to see if the drug reaches the brain and lowers inflammation linked to these diseases. Participants took baricitinib pills for 24 weeks, and researchers measured drug levels and inflammatory markers in spinal fluid.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital - AD Site
Charlestown, Massachusetts, 02129, United States
-
Massachusetts General Hospital - ALS Site
Boston, Massachusetts, 02129, United States